Company Profile for Valeant Pharmaceuticals International
Posted on: Friday, 25 November 2005, 12:00 CST
Valeant Pharmaceuticals International (NYSE:VRX) is a global, research-based specialty pharmaceutical company that discovers, develops, manufactures and markets products primarily in the areas of neurology, infectious disease and dermatology. Company: Valeant Pharmaceuticals International (NYSE:VRX) Headquarters Address: 3300 Hyland Avenue Costa Mesa, CA 92626 Main Telephone: 714-545-0100 Website: www.valeant.com Ticker: VRX(NYSE) Type of Organization: Public Industry: Health: Pharmaceutical Key Executives: CEO: Timothy C . Tyson CFO: Bary Bailey Public Relations Contact: Dan Springer Phone: 714-545-0100 xt. 3381 Email: dspringer@valeant.com Investor Relations Contact: Jeff Misakian Phone: 714-545-0100 xt. 3309 Email: jdmisakian@valeant.com
Source: Business Wire
Related Articles
- Valeant Pharmaceuticals Reports Third Quarter Financial Results
- Valeant Pharmaceuticals Reports Second Quarter Financial Results
- Valeant Pharmaceuticals and GlaxoSmithKline Announce Worldwide Collaboration Agreement for Retigabine
- Valeant Pharmaceuticals Unveils Diastat AcuDial for Safe, Rapid At-Home Treatment of Emergency Seizures; New Delivery System Allows for More Precise Dosing
- Valeant Pharmaceuticals to Initiate Retigabine Phase 3 Clinical Trials
- Valeant Pharmaceuticals to Initiate Clinical Development of Viramidine(R) in Japan; Valeant Forms Hepatitis C Advisory Board in Japan
- Valeant Pharmaceuticals Introduces Redesigned Migranal Delivery System at the American Headache Society's 47th Annual Meeting
- Valeant Pharmaceuticals Makes a Strong Showing at the Movement Disorder Society's 9th International Congress
- Valeant Pharmaceuticals Launches Tasmar in the European Union
 |
 |
User Comments (0)
RSS Feeds